The cost of Keytruda can vary based on several factors, including your insurance coverage. Coupons and drug savings programs can also lower the price you’ll pay for Keytruda. As with all ...

In July, Merck secured FDA approval for the use of Keytruda pre-surgery alongside chemotherapy in the neoadjuvant setting, as well as in the post-surgery (adjuvant) setting as a monotherapy ...

Merck (NYSE:MRK) said a Phase 3 study of its drug Keytruda in the treatment of a certain type of ovarian cancer met its primary endpoint of progression-free survival, but not its secondary ...

Just days after MSD claimed an FDA approval for Keytruda as a pre- and post-surgery option for early non-small cell lung cancer (NSCLC), Bristol-Myers Squibb has staked a claim for its rival PD-1 ...

Merck & Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end of the year, accelerating the company’s efforts to protect its top ...

Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in its portfolio. "Keytruda has ...

Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete response rate of 44%. Neoadjuvant Keytruda (pembrolizumab) given in a single cycle ...

Keytruda and Lenvima with chemotherapy improved progression-free survival and objective response rate but not overall survival in HER2-negative gastroesophageal adenocarcinoma. The safety profile of ...

Merck stock tumbled Monday after Summit Therapeutics' cancer drug outperformed blockbuster Keytruda in a study of lung cancer ...

Merck & Co.’s Keytruda is the world’s best-selling drug and has been a cancer juggernaut for more than a decade, scoring its 40th indication in June and adding yet another in late September.

Adagene (ADAG) announced updated clinical data from ADG126 in microsatellite stable colorectal cancer, MSS CRC, at the ASCO Gastrointestinal ...

In extending patent protection for its primary cancer medication, Keytruda, Merck (NYSE:MRK) intends to introduce a subcutaneous form of it this year. It's important to also note that Merck is ...